| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14760584.2016.1116949 |
| P8608 | Fatcat ID | release_e6mx4f44szhg3pdes5rbev7yuq |
| P932 | PMC publication ID | 5523864 |
| P698 | PubMed publication ID | 26560015 |
| P5875 | ResearchGate publication ID | 283728781 |
| P50 | author | In-Kyu Yoon | Q88057483 |
| Anon Srikiatkhachorn | Q115624794 | ||
| P2860 | cites work | Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host | Q23925011 |
| The global distribution and burden of dengue | Q24628768 | ||
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered | Q24736974 | ||
| Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion | Q24736978 | ||
| From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine | Q24737418 | ||
| The dengue vaccine pipeline: Implications for the future of dengue control | Q26314683 | ||
| Utilizing population variation, vaccination, and systems biology to study human immunology | Q26799374 | ||
| COMPASS identifies T-cell subsets correlated with clinical outcomes | Q27314516 | ||
| Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E | Q27469788 | ||
| Secreted NS1 of Dengue Virus Attaches to the Surface of Cells via Interactions with Heparan Sulfate and Chondroitin Sulfate E | Q27481677 | ||
| Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus | Q40441111 | ||
| Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence | Q40500253 | ||
| TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients | Q40526154 | ||
| Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand | Q40539101 | ||
| Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice | Q40552138 | ||
| Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren | Q40579912 | ||
| Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever | Q40631748 | ||
| Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever | Q40748542 | ||
| Dengue | Q85327578 | ||
| Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes | Q27485031 | ||
| Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II | Q27486409 | ||
| Differential Modulation of prM Cleavage, Extracellular Particle Distribution, and Virus Infectivity by Conserved Residues at Nonfurin Consensus Positions of the Dengue Virus pr-M Junction | Q27487116 | ||
| Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins | Q27649830 | ||
| The flavivirus precursor membrane-envelope protein complex: structure and maturation | Q27650164 | ||
| Structure of the immature dengue virus at low pH primes proteolytic maturation | Q27650165 | ||
| Structure of a Dengue Virus Envelope Protein Late-Stage Fusion Intermediate | Q27675461 | ||
| Cryo-EM structure of the mature dengue virus at 3.5-Å resolution | Q27675507 | ||
| The structural basis for serotype-specific neutralization of dengue virus by a human antibody | Q27681306 | ||
| Recognition determinants of broadly neutralizing human antibodies against dengue viruses | Q27697333 | ||
| Cross-reacting antibodies enhance dengue virus infection in humans | Q28281588 | ||
| A prospective study of dengue infections in Bangkok | Q28296365 | ||
| Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans | Q29616204 | ||
| Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial | Q29616259 | ||
| Research on dengue during World War II | Q29619423 | ||
| Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever | Q29619585 | ||
| Dengue | Q29619772 | ||
| Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants | Q29620637 | ||
| Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles | Q33358547 | ||
| Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue | Q33389673 | ||
| Hemophagocytosis in dengue: Comprehensive report of six cases | Q33402302 | ||
| Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. | Q33795001 | ||
| Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive | Q34088956 | ||
| Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever | Q34202440 | ||
| Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies | Q34351011 | ||
| Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis | Q34423720 | ||
| Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial | Q34428943 | ||
| Efficacy of a tetravalent dengue vaccine in children in Latin America. | Q34446032 | ||
| Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease | Q34487028 | ||
| An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells | Q34552933 | ||
| Intracellular Cytokine Production by Dengue Virus–specific T cells Correlates with Subclinical Secondary Infection | Q34754885 | ||
| Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year | Q34952330 | ||
| Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres | Q35082677 | ||
| Systems biology of vaccination for seasonal influenza in humans | Q35118722 | ||
| A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins | Q35138111 | ||
| Antibodies against immature virions are not a discriminating factor for dengue disease severity | Q35168403 | ||
| Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development | Q35195545 | ||
| Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine | Q35206695 | ||
| Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort | Q35221318 | ||
| Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans | Q35551374 | ||
| A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus | Q35654743 | ||
| Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies | Q35758626 | ||
| The entry machinery of flaviviruses. | Q35761248 | ||
| Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia | Q35856554 | ||
| Nomenclature for Immune Correlates of Protection After Vaccination | Q35948780 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial | Q36026210 | ||
| Revealing the microscale spatial signature of dengue transmission and immunity in an urban population | Q36066463 | ||
| Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults | Q36181531 | ||
| DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers | Q36352752 | ||
| Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity | Q37062703 | ||
| Reduced risk of disease during postsecondary dengue virus infections | Q37109553 | ||
| A Shorter Time Interval Between First and Second Dengue Infections Is Associated With Protection From Clinical Illness in a School-based Cohort in Thailand | Q37443026 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| HLA and other gene associations with dengue disease severity | Q37608071 | ||
| Molecular signatures of antibody responses derived from a systems biology study of five human vaccines | Q37625332 | ||
| Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection | Q38087545 | ||
| HIV vaccine efficacy and immune correlates of risk | Q38137212 | ||
| Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. | Q38362309 | ||
| T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? | Q39263024 | ||
| Contrasting associations of polymorphisms in FcγRIIa and DC-SIGN with the clinical presentation of dengue infection in a Mexican population. | Q39307546 | ||
| Primary dengue fever associated with hemophagocytic syndrome: a report of three imported cases, Bordeaux, France | Q39396096 | ||
| Human Dengue antibodies against structural and nonstructural proteins | Q39507601 | ||
| Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development | Q39521661 | ||
| Antibody-Mediated Destruction of Virus-Infected Cells | Q40121904 | ||
| Immune enhancement of viral infection | Q40132021 | ||
| Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination | Q40140017 | ||
| Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates | Q40148624 | ||
| Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement | Q40303277 | ||
| The development of a novel serotyping-NS1-ELISA to identify serotypes of dengue virus | Q40335732 | ||
| Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial | Q40342385 | ||
| Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. | Q40435198 | ||
| P433 | issue | 4 | |
| P921 | main subject | Dengue virus | Q476209 |
| P304 | page(s) | 455-465 | |
| P577 | publication date | 2015-11-11 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Immune correlates for dengue vaccine development | |
| P478 | volume | 15 |
| Q27116692 | A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates |
| Q91807708 | Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention |
| Q55244392 | Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice. |
| Q61053647 | Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy |
| Q28733418 | Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity |
| Q38652971 | Immune correlates of protection for dengue: State of the art and research agenda |
| Q28729784 | Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain |
| Q40040450 | Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine |
| Q40109446 | The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model |
Search more.